Cristalia Produtos Quimicos Farmaceuticos Ltda.

Cristalia Productos Quimicos Farmaceuticos Ltda.

Simone Rosatto

Maria Alice Bockelmann

Ogari Pacheco

Valter Russo

José Antônio Martins

Elisa Russo

Daniela Cecília Barel

Kesley Moraes Godinho De Oliveira

Matheus Puginna De Freitas

Cláudio Roberto Fuzeto

Thiago Boscaro Vernucci

The present invention has as objective the stabilization of a fluoroether compound against degradation by acid substances. The stabilizers proposed are selected among propylene glycol, polyethylene glycol, hexylene glycol, 1,3-butylene glycol and a saturated cyclic alcohol preferably menthol and are used for preparing stable pharmaceutical compositions of a fluoroether compound. Method for stabilizing a fluoroether compound and use of stabilizers agents for precluding the degradation of a fluoroether are also described.

Stable pharmaceutical composition of fluoroether compound for anesthetic use method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound

The present invention describes a new one ritonavir analogous compound that presents significantly superior activity in inhibition of HIV protease. There are also described the usage of the ritonavir analogous compound of the present invention or salt, ester or prodrug thereof as well as the usage of the compound and its pharmaceutical compositions in medicine, particularly, in the treatment of HIV infection, by itself or in combination with others anti-HIV drugs.

Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound

Growing community of inventors

Itapira, Brazil

Simone Rosatto